Shanghai Medicilon Inc.

  Amid the rapid advancement of AI, its application in drug development is gradually transforming the traditional pharmaceutical industry, driving drug research and development towards faster, stronger, and more precise innovation.  As a leader in the AI pharmaceutical field, Insilico Medicine has demonstrated impressive performance over the past few years. Whether in pipeline development, platform technology, or international collaborations, it has showcased its exceptional capabilities. Can AI-driven drug development ultimately lead to success in new drug research?  Can it effectively accelerate the drug development process through algorithms and data?  As a partner of Insilico Medicine, Medicilon is honored to invite Dr. Feng Ren, the joint CEO and Chief Scientific Officer of Insilico Medicine, to discuss and interpret the developments and trends of AI in new drug research and development. Dr. Feng Ren, joint CEO and Chief Scientific Officer of Insilico Medicine, ...

  Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement.  The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S. Medicilon: Build an AI-based one-stop preclinical R&D service platform At present, the AI+CRO model is rapidly gaining popularity around the world and is accelerating the transformation of the biopharmaceutical industry.  As a supporter of emerging technologies, Medicilon has been actively exploring the frontier technologies of drug development for 19 years.  In the field of AI pharmaceuticals, on the basis of collaboration with a number of AI innovative drug R&D companies, Medicilon will use the druggability evaluation and prediction platform of virtual drugs, drug intelligent target database, drug-molecule database, drug binding model database, drug designed AI generation model and AI virtual drug scree...

Date:  Sunday, May 14-1-4pm PDT160 E Tasman Dr Address:  160 East Tasman Drive San Jose, CA 95134 United States Organizer:  CBA (Chinese Bioscience Association) Co-organizers:  Medicilon, Q BAY center Media partner: CABS (Chinese-American Bio/Pharmaceutical Society) Gene- and RNA-based therapies show significant promise.  Gene editing aims to treat genetic disease through altering gene expression.  Programmable editing of nucleic acids offers significant therapeutic potential for a wide range of genetic diseases. Gene- and RNA-based therapies need substantial innovation to unlock full potential for patients.  Scaling digital and analytics in discovery and R&D is part of the solution.  Applying artificial intelligence (Al) to R&D for novel therapeutic modalities brings new opportunity. Let's explore the intersection of Al, gene editing, and RNA therapeutics! Dr. Ho Leung Ng the founder of Rise Bio Dr. Ng is the founder of Rise Bio, a startu...

  On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou. Medicilon (Hangzhou) will build as a CRO research center.  The nearly 8,000-square-meter R&D laboratory will focus on the biopharmaceuticals and AI pharmaceuticals, such as chemical drug synthesis research, compound synthesis, compound activity screening and other services.  This could accelerate the industrialization of research results.   About   Medicilon Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D. ...

  On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park.  This is another grand event following the opening of Medicilon (Hangzhou) on September 7. Medicilon (Baoshan) is located at the intersection of Panjing Road and Yueluo Road in Baoshan District, Shanghai.  The total investment of the project is RMB 1.57 billion, covering an area of 270,000 square meter, with a total construction area of over 150,000 square meters.  After the construction, Medicilon (Baoshan) will combine the most advanced technology and cutting-edge research fields of global drug research and development to establish a complete one-stop drug research and development platform with the ability to lead the new drug research and innovation, to establish different technology platform and to explore and form a higher level of scientific support for drug development and laboratory devel...